Capricor Therapeutics (NASDAQ: CAPR) Thursday priced its public offering of 4.412 million shares at $17 per share. The company's shares were down more than 12 percent in pre-market.
Capricor also granted the underwriters a 30-day option to purchase up to an additional 661,800 of its shares.
The company intends to use the proceeds from the offering to develop and manufacture its pipeline candidates, for working capital, and for general corporate purposes.
Piper Sandler & Co. and Oppenheimer & Co. Inc. are acting as the joint book-running managers for the offering, which is expected to close on October 18.
Capricor stock had closed at $20.51, down 5.05 percent on Wednesday. It has traded in the range of $2.68 - $23.40 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.